Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program

by Havrdova E, Cohen JA, Horakova D, Kovarova I, Meluzinova E
Published 2017-10-01